Can the shingles vaccine lower dementia risk? What newer U.S. studies show
New U.S. studies found lower dementia diagnosis rates after Shingrix, but they do not prove the vaccine prevents dementia. Here is what adults 50 and older should know now.
Neurology
-
-
After a TIA or clot-caused stroke, should you ask about asundexian?
A large 2026 trial suggests investigational asundexian may lower repeat stroke risk after certain recent strokes or high-risk TIAs without more major bleeding. It is worth asking about, but not a reason to change medicines on your own.
-
Auvelity for Alzheimer’s agitation: what families should know
Auvelity is now FDA-approved for agitation associated with dementia due to Alzheimer’s disease. Here is what families should know about who it is for, how it was studied, the main risks, why it is not a rescue medicine, and why medical evaluation and non-drug support still matter.
-
Do newer CGRP migraine medicines raise heart risk?
A new observational Neurology study is raising a question many migraine patients will ask: do CGRP preventive medicines increase cardiovascular risk? The short answer is that the study found an association, but it did not prove cause and effect, and the absolute risk increase was small.
-
Frequent migraines? New prevention studies may help guide choices
New migraine-prevention research adds to the evidence that some people do better with CGRP-targeting medicines, onabotulinumtoxinA, or older oral options. But the best choice still depends on migraine pattern, side effects, cost, and other health conditions.
-
A New Migraine Prevention Option for Some Kids: What the Latest Ajovy Study Means for Families
A newly published New England Journal of Medicine trial adds stronger evidence behind Ajovy for some children and teens with episodic migraine. The study found modest average benefit, not a cure, and the current U.S. label applies only to patients ages 6 to 17 who weigh 45 kg or more.
-
Alzheimer’s Blood Tests Are Moving Closer to Everyday Care: What They Can Tell You, and What They Still Can’t
Roche’s FDA-cleared pTau181 blood test brings Alzheimer’s biomarker testing closer to everyday care, but right now it is mainly for adults 55 and older who already have cognitive symptoms, and a positive result still usually needs more workup. ([accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K252163))
-
Alzheimer’s Anti-Amyloid Drugs in 2026: Who Qualifies, What Are the Risks, and What Medicare Covers
FDA-approved anti-amyloid drugs such as lecanemab are now in real-world use for early Alzheimer’s disease. Here’s who qualifies, what the main clinical trial showed, what ARIA risks mean, and how Medicare coverage works in the United States.
-
Anti-Amyloid Antibodies for Early Alzheimer’s: What FDA Approval Means for Patients, Risks, and Access in 2026
FDA traditional approval of lecanemab for early Alzheimer’s disease offers modest slowing of decline for some patients—but requires careful screening, MRI monitoring, and meeting Medicare coverage rules. Here’s what families should understand in 2026.
-
When Headache Medicine Backfires: What to Know About Medication Overuse Headache
Using headache medicines too often can sometimes make headaches worse instead of better. Here’s what U.S. experts say about medication overuse headache—how it happens, who’s at risk, and how to break the cycle safely.
-
Alzheimer’s Antibody Drugs in 2026: What Medicare Covers, Who Qualifies, and What Patients Should Know
Anti-amyloid antibody treatments such as lecanemab are now part of Alzheimer’s care in the United States—but only for certain patients. Here’s who qualifies, what Medicare covers, how MRI safety monitoring works, and what families should realistically expect.
-
Anti-Amyloid Alzheimer’s Drugs in 2026: Who Qualifies, What They Do, and What Families Should Know
FDA-approved anti-amyloid drugs like lecanemab can modestly slow early Alzheimer’s disease—but they are not cures. Here’s who qualifies, what the clinical trials showed, the real risks, and how Medicare coverage works in 2026.
-
Stroke in the United States: What the Latest CDC Data Means for Your Brain Health
Stroke remains a leading cause of death and long-term disability in the United States. Here’s what the most recent CDC data shows, who is at highest risk, and what everyday prevention steps can lower your chances.
-
Why Some People Never Feel Pain: What Congenital Insensitivity to Pain Teaches Us About the Human Body
A rare condition called congenital insensitivity to pain may sound like a superpower. In reality, it can be life-threatening. Here’s what researchers know, what remains a mystery, and what it means for everyday health.
-
Hearing Loss in the U.S.: What Public Health Experts Want Families to Know in 2026
Hearing loss affects millions of Americans across all ages. Here’s what current public health guidance says about causes, prevention, over-the-counter hearing aids, and when to seek care.
-
Brain | Headache | Medical Care | Neurology
Headaches in 2026: When to Worry, What Works, and What the Evidence Says
Headaches are common, but not all are the same. Here’s what U.S. health experts say about types of headaches, warning signs, treatment options, and when to seek medical care.
-
Brain | Dementia | Neurology | Public Health
Brain Health in 2026: What the Latest Public Health Guidance Says About Protecting Your Mind
New and ongoing guidance from U.S. public health agencies highlights practical steps people can take to lower their risk of stroke, dementia, and other brain-related conditions. Here’s what matters most for everyday life.
-
Brain Health in 2026: What the Evidence Says About Lowering Dementia Risk
Dementia is not an inevitable part of aging. Here’s what major public health agencies and medical journals say about protecting brain health—and what it means for you and your family.
-
Hearing Loss in the United States: What’s New, Who’s at Risk, and What You Can Do
Hearing loss affects millions of Americans across all ages. Here’s what the latest federal guidance and research say about risk factors, over-the-counter hearing aids, prevention, and when to seek care.
-
Headache: What Different Types Mean and When to Seek Care
Most headaches are not dangerous, but some need medical attention. Here’s how to tell the difference, what current guidance says about treatment, and when to see a doctor.
-
Stroke in the United States: Early Warning Signs, Treatment Windows, and What Prevention Really Means
Stroke remains a leading cause of death and long-term disability in the United States. Here’s what the latest public health guidance says about symptoms, treatment timing, risk factors, and practical prevention steps.
-
When to See a Neurologist: Symptoms That Point to Nerve or Brain Issues
Knowing when to see a neurologist can prevent complications and speed recovery. This article explains the key warning signs of nerve or brain problems—sudden weakness or numbness, severe or new headaches, changes in vision, speech, or balance, seizures or tremors, memory or thinking issues, and persistent tingling, pain, or back/neck symptoms that radiate into a limb—and flags emergencies like possible stroke (face droop, arm weakness, speech trouble: call emergency services). It also outlines what to expect at an appointment, including a neurological exam and tests such as MRI/CT, EEG, or EMG, and the range of conditions neurologists treat, from migraines and neuropathy to epilepsy and multiple sclerosis. Patients and caregivers will find practical tips for tracking symptoms, preparing questions, and seeking timely referrals, with reassurance that early evaluation leads to safer, tailored care and better outcomes.
End of content
End of content